

CHAPTER 19

ANDROGENS, ENDOMETRIUM AND RECEPTIVITY GENES

Onder CELIK, Senol SENTURK

Does the endometrium age?

In contrast to “ovarian aging” data coming from endometrial aging studies are contradictory. By using oocyte donation model one study reported that endometrial aging does not affect fertility outcome. Other studies concluded that age related decline in implantation rates could be associated with decreased endometrial receptivity. In a recent study conducted by Sekhon et al. investigated the impact of endometrial age on implantation and clinical pregnancy rates in women undergoing in vitro fertilization. They used either donor or autologous oocyte while controlling for oocyte quality by using genetic screening test. They have reported that the number of retrieved oocytes decreased 2.5% per each additional year of oocyte age. In contrast, insignificant decline in the endometrial thickness per each additional year of recipient age has been reported. They have concluded that endometrial aging does not contribute to age-related decline in fertility. On the other hand, it should be noted that endometrial thickness is not main determinant of the endometrium receptivity. Decline in endometrial thickness does not mean decline in endometrial receptivity. While some women having increased endometrial thickness can exhibit low implantation rates women having decreased endometrial thickness may show high implantation rates (1-3).

Is endometrium an intracrine organ?

All extra-gonadal tissues consist of intracrine enzymes which able to transform androgens to estrogens and its variants. This cell specific intracrinology leads to production of androgens and estrogens locally according to the cell specific needs without biologically significant release of this steroids into blood circulation. Transformation of the DHEA to androgens and estrogens in extra-gonadal tissues are restricted to the altered expressions of the steroidogenic enzymes, making the metabolism of DHEA tissue-specific. Hence, peripheral interconversion of DHEA ranges from none in the some target tissues to various in the others (4).

References

1. Borini A, Bianchi L, Violini F, Maccolini A, Cattoli M, Flamigni C. Oocyte donation program: pregnancy and implantation rates in women of different ages sharing oocytes from single donor. *Fertil Steril* 1996;65:94-7.
2. Cano F, Simón C, Remohí J, Pellicer A. Effect of aging on the female reproductive system: evidence for a role of uterine senescence in the decline in female fecundity. *Fertil Steril* 1995;64:584-9.
3. Sekhon L, Lee JA, Whitehouse M, Mukherjee T, Sandler B, Grunfeld L, Copperman AB. Using new technology to ask and old question: does the uterus age? American Society for Reproductive Medicine 2015 Annual Meeting October 17 to 21, 2015 Baltimore, Maryland, USA (Abstract).
4. Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. *Climacteric*. 2013;16:205–13.
5. Carneiro MM, Morsch DM, Camargos AF, Reis FM, Spritzer PM. Androgen receptor and 5 α -reductase are expressed in pelvic endometriosis. *BJOG* 2008;115:113–7.
6. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. *J Mol Endocrinol* 2000;25:35–42.
7. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. *Pharmacol Rev* 2005;57:359–83.
8. Hausknecht V, Lopez de la Osa E, Gursipe E. In vitro metabolism of C19 steroids in human endometrium. *J Steroid Biochem* 1982;17:621–9.
9. Bukulmez O, Hardy DB, Carr BR, Auchus RJ, Toloubeydokhti T, Word RA, et al. Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. *J Clin Endocrinol Metab* 2008;93:3471–7.
10. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. *Mol Endocrinol*. 1999;13:239–53.
11. Michael MD, Kilgore MW, Morohashi K, Simpson ER. Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19) gene in the ovary. *J Biol Chem* 1995;270:13561–6.
12. Tseng L. Estrogen synthesis in human endometrial epithelial glands and stromal cells. *J Steroid Biochem* 1984;20:877–81.
13. Tseng L, Mazella J, Mann WJ, Chumas J. Estrogen synthesis in normal and malignant human endometrium. *J Clin Endocrinol Metab* 1982;55:1029–31.
14. Taylor HS, Arici A, Olive D, Igarashi P. HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. *J Clin Invest* 1998;101:1379–84.
15. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. *Hum Reprod* 2006;21:2845–9.
16. Zanatta A, Rocha AM, Carvalho FM, Pereira RM, Taylor HS, Motta EL, et al. The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review. *J Assist Reprod Genet* 2010;27:701–10.
17. Labrie F. DHEA after menopause – sole source of sex steroids and potential sex steroid deficiency treatment. *Menopause Management* 2010;19:14–24.
18. Kowalski AA, Vale-Cruz DS, Simmen FA, Simmen RC. Uterine androgen receptors: roles in estrogen-mediated gene expression and DNA synthesis. *Biol Reprod* 2004;70:1349–57.
19. Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). *Reprod Biol Endocrinol* 2010;8:140.

20. Gleicher N, Weghofer A, Barad DH. Discordances between follicle stimulating hormone (FSH) and anti-Mullerian hormone (AMH) in female infertility. *Reprod Biol Endocrinol* 2010;8:64.
21. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. *Reprod Biomed Online* 2010;21:360–5.
22. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. *Am J Epidemiol* 2000;152:463–73.
23. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. *Hum Reprod* 2000;15:2129–32.
24. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. *Fertil Steril* 1998;70:107–10.
25. Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. *Climacteric*. 2013;16:205–13.
26. Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. *Gynecol Endocrinol* 2013;29:940-3.
27. Lim H, Ma L, Ma WG, Maas RL, Dey SK. Hoxa-10 regulates uterine stromal cell responsiveness to progesterone during implantation and decidualization in the mouse. *Mol Endocrinol* 1999;13:1005–17.
28. Celik N, Aydin S, Ugur K, Yardim M, Acet M, Yavuzkir S, Sahin İ, Celik O. Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS. *Cell Mol Biol (Noisy-le-grand)*. 2018 Dec 31;64(15):7-12.
29. Klein J, Sauer MV. Oocyte donation. *Best Pract Res Clin Obstet Gynaecol*. 2002;16:277–91.
30. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J ClinEndocrinol Metab* 1997;82:3498–505.
31. Li TC, Aplin JD, Warren A, Graham RA, Dockery P, Cooke ID. Endometrial responses to three different progestins in artificial cycles: a prospective, crossover study. *Fertil. Steril*. 1994;62:191–3.
32. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocr Rev* 2003;24:152–82.
33. Gleicher N, Kim A, Weghofer A, Kushnir VA, Shohat-Tal A, Lazzaroni E, et al. Hypoandrogenism in association with diminished functional ovarian reserve. *Hum Reprod* 2013;28:1084–91.
34. Horie K, Takakura K, Imai K, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. *Hum Reprod* 1992;7:1461–6.
35. Dart DA, Waxman J, Aboagye EO, Bevan CL. Visualising androgen receptor activity in male and female mice. *PLoS ONE* 2013;8:e71694.
36. Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, et al. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. *Proc Natl Acad Sci U S A* 2004;101:11209–14.
37. Critchley HO, Saunders PT. Hormone receptor dynamics in a receptive human endometrium. *Reprod Sci* 2009;16:191–9.
38. Mertens HJ, Heineman MJ, Theunissen PH, de Jong FH, Evers JL. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. *Eur J Obstet Gynecol Reprod Biol*. 2001;98:58–65.
39. Chandrasekhar Y, Armstrong DT, Kennedy TG. Implantation delay and anti-deciduogenic activity in the rat by the anti-androgen, hydroxyflutamide. *Biol Reprod* 1990;42:120–5.

40. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. *Endocrinol. Metab. Clin. North Am* 1998;27:989–1006.
41. Kang Z, Pirskanen A, Janne OA, Palvimo JJ. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. *J Biol Chem* 2002;277:48366–71.
42. Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW, et al. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. *Proc Natl Acad Sci USA* 2006;103:16272–7.
43. Gleicher N, Kim A, Weghofer A, Kushnir VA, Shohat-Tal A, Lazzaroni E, et al. Hypoandrogenism in association with diminished functional ovarian reserve. *Hum Reprod* 2013;28:1084–91.
44. Beato M, Truss M, Chavez S. Control of transcription by steroid hormones. *Ann N Y Acad Sci* 1996;784:93–123.
45. Sahlin L, Norstedt G, Eriksson H. Androgen regulation of insulin-like growth factor-I and the estrogen receptor in the rat uterus and liver. *J Steroid Biochem Mol Biol* 1994;51:57–66.
46. Lynch VJ, Brayer K, Gellersen B, Wagner GP. HoxA-11 and FOXO1A cooperate to regulate decidual prolactin expression: towards interferring the core transcriptional regulators of decidual genes. *PLoS ONE* 2009;4:e6845.
47. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. *Endocr Rev* 1996;17:639–69.
48. Marshall E, Lowrey J, MacPherson S, Maybin JA, Collins F, Critchley HO, et al. In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. *J Clin Endocrinol Metab* 2011;96:E1746–55.
49. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor a in luminal breast cancer cells. *Mol Endocrinol* 2012;26:1941–52.
50. Weihua Z, Ekman J, Almkvist A, Saji S, Wang L, Warner M, et al. Involvement of androgen receptor in 17beta-estradiol-induced cell proliferation in rat uterus. *Biol Reprod* 2002;67:616–23.
51. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, Holder D, et al. Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. *Endocrinology* 2005;146:564–78.
52. Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, et al. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. *Proc Natl Acad Sci U S A* 2004;101:11209–14.
53. Hu SJ, Ren G, Liu JL, Zhao ZA, Yu YS, Su RW, et al. MicroRNA expression and regulation in mouse uterus during embryo implantation. *J Biol Chem* 2008;283:23473–84.
54. Gonzalez-Diddi M, Komisaruk B, Beyer C. Differential effects of testosterone and dihydrotestosterone on the diverse uterine tissues of the ovariectomized rat. *Endocrinology* 1972;91:1129–32.
55. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, et al. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. *J Clin Endocrinol Metab* 2002;87:2960–6.
56. Zhang X, Croy BA. Maintenance of decidual cell reaction by androgens in the mouse. *Biol Reprod* 1996;55:519–24.
57. McGrath M, Lee IM, Hankinson SE, Kraft P, Hunter DJ, Buring J, et al. Androgen receptor polymorphisms and endometrial cancer risk. *Int J Cancer* 2006;118:1261–8.
58. Narukawa S, Kanzaki H, Inoue T, Imai K, Higuchi T, Hatayama H, et al. Androgens induce prolactin production by human endometrial stromal cells in vitro. *J Clin Endocrinol Metab* 1994;78:165–8.
59. Kaminska K, Bogacka I, Wasielak M, Bogacki M. Peroxisome proliferator activated receptors and their role in reproduction. *Med Vet* 2008;64:533–6.

60. Yang J, Chen L, Zhang X, Zhou Y, Zhang D, Huo M, et al. PPARs and female reproduction: evidence from genetically manipulated mice. *PPAR Res* 2008;2008:723243.
61. Bogacka I, Bogacki M, Kurzyńska A, Chojnowska K. The involvement of peroxisome proliferator activated receptors (PPARs) in prostaglandin F_{2α} production by porcine endometrium. *Reprod Biol* 2013;13:309–16.
62. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling. *Reprod Biol Endocrinol* 2005;3:41.
63. Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. *Mol Pharmacol* 1996;50:67–74.
64. Mandard S, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. *Cell Mol Life Sci* 2004;61:393–416.
65. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. *PPAR Res* 2010;2010.
66. Patel MA, Katyare SS. Dehydroepiandrosterone (DHEA) treatment stimulates oxidative energy metabolism in the cerebral mitochondria from developing rats. *Int J Dev Neurosci* 2006;24:327–34.